TNF and inflammatory bowel disease: Furthermore, case-control studies did not identify concomitant immunosuppressive therapy as a risk factor for malignancy development, with controls consisting of IBD patients who had never been treated with TNFα inhibitors, thiopurines, or methotrexate [16,20,22,23].